Alkermes plc (ALKS) announced Monday morning that it has received a refusal to file letter from the FDA regarding its New Drug Application for ALKS 5461. The FDA stated that additional well-controlled clinical trials are needed.
from RTT - Before the Bell https://ift.tt/2JdYXbw
via IFTTT
No comments:
Post a Comment